摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-bromo-8-(tert-butoxycarbonyl)-6,7,8,9-tetrahydro-5H-imidazo[1,5-a][1,4]diazepine-1-carboxylic acid | 1094091-91-4

中文名称
——
中文别名
——
英文名称
3-bromo-8-(tert-butoxycarbonyl)-6,7,8,9-tetrahydro-5H-imidazo[1,5-a][1,4]diazepine-1-carboxylic acid
英文别名
3-bromo-8-[(2-methylpropan-2-yl)oxycarbonyl]-5,6,7,9-tetrahydroimidazo[1,5-a][1,4]diazepine-1-carboxylic acid
3-bromo-8-(tert-butoxycarbonyl)-6,7,8,9-tetrahydro-5H-imidazo[1,5-a][1,4]diazepine-1-carboxylic acid化学式
CAS
1094091-91-4
化学式
C13H18BrN3O4
mdl
——
分子量
360.208
InChiKey
DQMCEWVYRPTWPH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    533.7±60.0 °C(Predicted)
  • 密度:
    1.60±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    84.7
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain
    申请人:Cara Therapeutics, Inc.
    公开号:US07517874B2
    公开(公告)日:2009-04-14
    The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.
    本发明提供了具有I式结构的取代咪唑杂环化合物。还提供了公认的药用盐、酸盐、水合物、溶剂化合物和I式化合物的立体异构体。这些化合物可用作大麻素受体调节剂,并用于预防和治疗与大麻素受体相关的疾病和症状,如疼痛、炎症和瘙痒症。
  • Uses of substituted imidazoheterocycles
    申请人:Beckett R. Paul
    公开号:US08859538B2
    公开(公告)日:2014-10-14
    The present invention provides a method of prophylaxis, treatment or inhibition of a cannabinoid receptor-associated disease, disorder or condition in a mammalian subject, the method comprising administering to the subject a compound having the structure of formula I or a pharmaceutically acceptable salt, acid salt, hydrate or stereoisomer thereof, wherein the cannabinoid receptor-associated disease, disorder or condition is pain or an inflammatory disease, disorder or condition, and wherein formula I is as follows: wherein Rb, Rc, Z, Y and m are defined in the specification.
    本发明提供了一种预防、治疗或抑制哺乳动物主体中的大麻素受体相关疾病、疾病或状况的方法,该方法包括向主体投予结构式I或其药学上可接受的盐、酸盐、水合物或立体异构体的化合物,其中大麻素受体相关疾病、疾病或状况是疼痛或炎症性疾病、疾病或状况,式I如下:其中Rb、Rc、Z、Y和m在规范中定义。
  • Substituted imidazoheterocycles
    申请人:Beckett R. Paul
    公开号:US08431565B2
    公开(公告)日:2013-04-30
    The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.
    本发明提供了具有I式结构的取代咪唑杂环化合物,同时还提供了I式化合物的药学上可接受的盐、酸盐、水合物、溶剂物和立体异构体。这些化合物可用作大麻素受体的调节剂,并用于预防和治疗与大麻素受体相关的疾病和病症,如疼痛、炎症和瘙痒。
  • USES OF SUBSTITUTED IMIDAZOHETEROCYCLES
    申请人:Beckett R. Paul
    公开号:US20110034443A1
    公开(公告)日:2011-02-10
    The present invention provides methods of prevention and treatment of cannabinoid receptor-associated diseases and conditions, wherein the method includes administering a substituted imidazoheterocyclic compounds having the structure of formula I or a pharmaceutically acceptable salt, acid salt, hydrate, solvate or stereoisomer of a compound having the structure of formula I. The cannabinoid receptor-associated diseases and conditions preventable or treatable by the methods of the present invention include pain, inflammation and pruritis.
    本发明提供了预防和治疗与大麻素受体相关的疾病和症状的方法,其中该方法包括给予具有I式结构的取代咪唑杂环化合物或其药学上可接受的盐、酸盐、水合物、溶剂物或立体异构体。本发明的方法可预防或治疗与大麻素受体相关的疾病和症状,包括疼痛、炎症和瘙痒。
  • US7517874B2
    申请人:——
    公开号:US7517874B2
    公开(公告)日:2009-04-14
查看更多

同类化合物

脱氧助间型霉素 化合物RK-33 8-叔-丁基1-乙基6,7-二氢-5H-咪唑并[1,5-A][1,4]二氮杂卓-1,8(9H)-二甲酸基酯 8-(叔丁氧羰基)-6,7,8,9-四氢-5H-咪唑并[1,5-A][1,4]二氮杂-1-羧酸 6-羟基-4,5,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-8(1H)-酮 5-(8-羟基-7,8-二氢-4H-咪唑并[5,4-d][1,3]二氮杂卓-3-基)-3-(羟基甲基)环戊-3-烯-1,2-二醇 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 3-[(2-羟基乙氧基)甲基]-3,4,7,8-四氢咪唑并[4,5-d][1,3]二氮杂卓-8-醇 1H-咪唑并[1,5-d〕〔1,4]二氮杂(9CI) 1,4,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-5,8-二酮 (9ci)-1H-咪唑并[1,2-a][1,4]二氮杂卓 5-methylthio-11H-imidazo[1,2-c][1,3]benzodiazepine 2-methoxy-1,4,7-trimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-5,7-diphenyl-4,5,7,8-tetrahydroimidazo<4,5-e><1,3>diazepin-6-one 6-amino-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione [3-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8 tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol]-5'-phosphoric Acid-(3-dodecylmercapto-2-decyloxy)-propyl Ester (4S)-4-benzyl-2-(2,5-dihydroxyphenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one (4S)-4-benzyl-2-(2,5-dimethoxyphenyl)-3,4-dihydro-5H-pyrido[10,20:1,2]imidazo [4,5-d][1,3]diazepin-5-one (4S)-4-methyl-2-(1-naphthyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 6-amino-1-(2'-deoxy-β-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione 6-amino-1-(2'-deoxy-α-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione (4S)-4-methyl-2-(4-acetamidophenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 5-(4-methyl-1-piperazinyl)-11H-imidazo[1,2-c][1,3]benzodiazepine monomaleate (8R)-3-[(4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol (R)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 6-(decylamino)-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-imidazo[4,5-e][1,3]diazepine-4,8-dione (13S)-11-(4-methoxyphenyl)-13-methyl-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7,11-pentaen-14-one (8R)-3-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 8-Ketodeoxycoformycin 2'-chloropentostatin CO-Vidarabine (8R)-3-[(1S,2R,4R)-2-(benzoyloxymethyl)-1-benzoyloxycyclopent-4-yl]-8-[(tert-butyldimethylsilyl)oxy]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepine (8R)-3-Benzyl-6-(tert-butoxycarbonyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine (8R)-3-(2'-Cyanoethyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine 4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4,7-diethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4,6-diamino-6-(ethylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 4,5-dihydro-8H-6-(N-hexadecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-tetradecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-octadecyl)amino-1-(2-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,6-diamino-6-(octadecylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 8-Imino-2,4-dimethyl-7-phenyl-7,8-dihydro-4H-1,2a,4,5,7-pentaaza-cyclopenta[cd]azulene-3,6-dione 1,4-dimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 11H-imidazo[1,2-c][1,3]benzodiazepine-5(6H)-thione (8R)-3-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 2-(4-Chloro-benzylcarbamoyl)-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-hexanoic acid benzyl ester (13S)-13-(1H-indol-3-ylmethyl)-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7-tetraene-11,14-dione